{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:09:46Z","timestamp":1777396186493,"version":"3.51.4"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40122-025-00769-9","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T17:13:25Z","timestamp":1756660405000},"page":"1573-1595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-Effectiveness of a High-Concentration (179\u00a0mg) Capsaicin Patch for the Treatment of Patients with Peripheral Neuropathic Pain in Scotland"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1145-6444","authenticated-orcid":false,"given":"Rita","family":"Freitas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3279-9588","authenticated-orcid":false,"given":"Marjolijn","family":"van Keep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashanth","family":"Kandaswamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3233-0060","authenticated-orcid":false,"given":"Anja","family":"Pr\u00fcfert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miranda","family":"Ager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-4806","authenticated-orcid":false,"given":"Marielle","family":"Eerdekens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"issue":"1","key":"769_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/j.pain.0000000000001365","volume":"160","author":"J Scholz","year":"2019","unstructured":"Scholz J, Finnerup NB, Attal N, Aziz Q, Baron R, Bennett MI, Benoliel R, Cohen M, Cruccu G, Davis KD, et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019;160(1):53\u20139. https:\/\/doi.org\/10.1097\/j.pain.0000000000001365.","journal-title":"Pain"},{"key":"769_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/CEOR.S81396","volume":"8","author":"H Liedgens","year":"2016","unstructured":"Liedgens H, Obradovic M, De Courcy J, Holbrook T, Jakubanis R. A burden of illness study for neuropathic pain in Europe. Clinicoecon Outcomes Res. 2016;8:113\u201326. https:\/\/doi.org\/10.2147\/CEOR.S81396.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"2","key":"769_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000001066","volume":"8","author":"G Baskozos","year":"2023","unstructured":"Baskozos G, H\u00e9bert HL, Pascal MMV, Themistocleous AC, Macfarlane GJ, Wynick D, Bennett DLH, Smith BH. Epidemiology of neuropathic pain: an analysis of prevalence and associated factors in UK Biobank. PAIN Rep. 2023;8(2): E1066. https:\/\/doi.org\/10.1097\/PR9.0000000000001066.","journal-title":"PAIN Rep"},{"issue":"7","key":"769_CR4","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/papr.12533","volume":"17","author":"C P\u00e9rez","year":"2017","unstructured":"P\u00e9rez C, Margarit C, S\u00e1nchez-Magro I, Antonio A, Villoria J. Chronic pain features relate to quality of life more than physiopathology: a cross-sectional evaluation in pain clinics. Pain Pract. 2017;17(7):866\u201378. https:\/\/doi.org\/10.1111\/papr.12533.","journal-title":"Pain Pract"},{"issue":"3","key":"769_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10198-006-0025-2","volume":"8","author":"A Berger","year":"2007","unstructured":"Berger A, Kramarz P, Kopperud G, Edelsberg J, Oster G. Economic impact of shifting the locus of care for neuropathic pain from specialists to general practitioners. Eur J Health Econ. 2007;8(3):245\u201351. https:\/\/doi.org\/10.1007\/s10198-006-0025-2.","journal-title":"Eur J Health Econ"},{"key":"769_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.2","author":"L Colloca","year":"2017","unstructured":"Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, Freeman R, Truini A, Attal N, Finnerup NB, et al. Neuropathic pain. Nat Rev Dis Primers. 2017. https:\/\/doi.org\/10.1038\/nrdp.2017.2.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"769_CR7","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/j.pain.2011.09.014","volume":"152","author":"N Attal","year":"2011","unstructured":"Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira D. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain. 2011;152(12):2836\u201343. https:\/\/doi.org\/10.1016\/j.pain.2011.09.014.","journal-title":"Pain"},{"issue":"5","key":"769_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S1474-4422(25)00068-7","volume":"24","author":"N Soliman","year":"2025","unstructured":"Soliman N, Moisset X, Ferraro MC, de Andrade DC, Baron R, Belton J, Bennett DLH, Calvo M, Dougherty P, Gilron I, et al. Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurol. 2025;24(5):413\u201328. https:\/\/doi.org\/10.1016\/S1474-4422(25)00068-7.","journal-title":"Lancet Neurol"},{"issue":"3","key":"769_CR9","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.4065\/mcp.2009.0649","volume":"85","author":"RH Dworkin","year":"2010","unstructured":"Dworkin RH, O\u2019Connor AB, Audette J, Baron R, Gourlay GK, Haanp\u00e4\u00e4 ML, Kent JL, Krane EJ, LeBel AA, Levy RM, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3):S3\u201314. https:\/\/doi.org\/10.4065\/mcp.2009.0649.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"769_CR10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.jvs.2015.08.010","volume":"62","author":"Finnerup, Attal, Haroutounian","year":"2015","unstructured":"Finnerup, Attal, Haroutounian. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. J Vasc Surg. 2015;62(4):1091. https:\/\/doi.org\/10.1016\/j.jvs.2015.08.010.","journal-title":"J Vasc Surg"},{"issue":"1","key":"769_CR11","first-page":"49","volume":"5","author":"O Gheith","year":"2016","unstructured":"Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2016;5(1):49\u201356.","journal-title":"J Nephropharmacol"},{"key":"769_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-018-0732-4","author":"GT Russo","year":"2018","unstructured":"Russo GT, De Cosmo S, Viazzi F, Mirijello A, Ceriello A, Guida P, Giorda C, Cucinotta D, Pontremoli R, Fioretto P. Diabetic kidney disease in the elderly: prevalence and clinical correlates. BMC Geriatr. 2018. https:\/\/doi.org\/10.1186\/s12877-018-0732-4.","journal-title":"BMC Geriatr"},{"issue":"11","key":"769_CR13","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1111\/pme.12845","volume":"16","author":"M Yang","year":"2015","unstructured":"Yang M, Qian C, Liu Y. Suboptimal treatment of diabetic peripheral neuropathic pain in the United States. Pain Med. 2015;16(11):2075\u201383. https:\/\/doi.org\/10.1111\/pme.12845.","journal-title":"Pain Med"},{"key":"769_CR14","unstructured":"European Medicines Agency (EMA). Qutenza EPAR. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/qutenza#authorisation-details-section. Accessed 5 May 2025."},{"key":"769_CR15","unstructured":"Food and Drug Administration (FDA). Qutenza US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/022395s024lbl.pdf. Accessed 5 May 2025."},{"key":"769_CR16","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.2147\/JPR.S213912","volume":"12","author":"P Anand","year":"2019","unstructured":"Anand P, Elsafa E, Privitera R, Naidoo K, Yiangou Y, Donatien P, Gabra H, Wasan H, Kenny L, Rahemtulla A, et al. Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification. J Pain Res. 2019;12:2039\u201352. https:\/\/doi.org\/10.2147\/JPR.S213912.","journal-title":"J Pain Res"},{"key":"769_CR17","doi-asserted-by":"publisher","unstructured":"Vinik AI, Perrot S, Vinik EJ, Pazdera L, Stoker M, Snijder RJ, Ortega E, Katz N. Repeat treatment with capsaicin 8% patch (179 mg capsaicin cutaneous patch): effects on pain, quality of life, and patient satisfaction in painful diabetic peripheral neuropathy: an open-label, randomized controlled clinical trial. J Curr Med Res Opin. 2019;2(12):388\u2013401. https:\/\/doi.org\/10.15520\/jcmro.v2i12.242.","DOI":"10.15520\/jcmro.v2i12.242"},{"issue":"1","key":"769_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jpain.2016.09.008","volume":"18","author":"R-P Simpson","year":"2017","unstructured":"Simpson R-P, Van S, Jacobs S, Schregardus L, Lambourg K. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J Pain. 2017;18(1):42\u201353. https:\/\/doi.org\/10.1016\/j.jpain.2016.09.008.","journal-title":"J Pain"},{"key":"769_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0752-7","author":"AI Vinik","year":"2016","unstructured":"Vinik AI, Perrot S, Vinik EJ, Pazdera L, Jacobs H, Stoker M, Long SK, Snijder RJ, van der Stoep M, Ortega E, et al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol. 2016. https:\/\/doi.org\/10.1186\/s12883-016-0752-7.","journal-title":"BMC Neurol"},{"issue":"6","key":"769_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.36076\/ppj.2021.24.453","volume":"24","author":"E Viel","year":"2021","unstructured":"Viel E, Eerdekens M, Kandaswamy P. Treatment impact on patient-reported outcomes in peripheral neuropathic pain: comparing single intervention with topical high-concentration capsaicin to daily oral pregabalin. Pain Physician. 2021;24(6):453\u201363. https:\/\/doi.org\/10.36076\/ppj.2021.24.453.","journal-title":"Pain Physician."},{"issue":"2","key":"769_CR21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ejp.731","volume":"20","author":"M Haanp\u00e4\u00e4","year":"2016","unstructured":"Haanp\u00e4\u00e4 M, Cruccu G, Nurmikko TJ, McBride WT, Docu Axelarad A, Bosilkov A, Chambers C, Ernault E, Abdulahad AK. Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain. Eur J Pain. 2016;20(2):316\u201328. https:\/\/doi.org\/10.1002\/ejp.731.","journal-title":"Eur J Pain"},{"issue":"10","key":"769_CR22","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1097\/AJP.0000000000000473","volume":"33","author":"R G\u00e1lvez","year":"2017","unstructured":"G\u00e1lvez R, Navez M-L, Moyle G, Maih\u00f6fner C, Stoker M, Ernault E, Nurmikko TJ, Attal N. Capsaicin 8% patch repeat treatment in nondiabetic peripheral neuropathic pain. Clin J Pain. 2017;33(10):921\u201331. https:\/\/doi.org\/10.1097\/AJP.0000000000000473.","journal-title":"Clin J Pain"},{"issue":"10","key":"769_CR23","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1093\/pm\/pnab113","volume":"22","author":"R Freynhagen","year":"2021","unstructured":"Freynhagen R, Argoff C, Eerdekens M, Engelen S, Perrot S. Progressive response to repeat application of capsaicin 179 mg (8% w\/w) cutaneous patch in peripheral neuropathic pain: comprehensive new analysis and clinical implications. Pain Med. 2021;22(10):2324\u201336. https:\/\/doi.org\/10.1093\/pm\/pnab113.","journal-title":"Pain Med"},{"issue":"5","key":"769_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.neurol.2020.01.361","volume":"176","author":"X Moisset","year":"2020","unstructured":"Moisset X, Bouhassira D, Avez Couturier J, Alchaar H, Conradi S, Delmotte MH, Lanteri-Minet M, Lefaucheur JP, Mick G, Piano V, et al. Pharmacological and non-pharmacological treatments for neuropathic pain: systematic review and French recommendations. Rev Neurol (Paris). 2020;176(5):325\u201352. https:\/\/doi.org\/10.1016\/j.neurol.2020.01.361.","journal-title":"Rev Neurol (Paris)"},{"issue":"7","key":"769_CR25","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.neurol.2021.07.004","volume":"177","author":"X Moisset","year":"2021","unstructured":"Moisset X, Bouhassira D, Attal N. French guidelines for neuropathic pain: an update and commentary. Rev Neurol (Paris). 2021;177(7):834\u20137. https:\/\/doi.org\/10.1016\/j.neurol.2021.07.004.","journal-title":"Rev Neurol (Paris)"},{"issue":"10","key":"769_CR26","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","volume":"28","author":"U Blonde","year":"2022","unstructured":"Blonde U, Reddy M, Berga B, Chandrasekaran D, Einhorn G, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan\u20142022 update. Endocr Pract. 2022;28(10):923\u20131049. https:\/\/doi.org\/10.1016\/j.eprac.2022.08.002.","journal-title":"Endocr Pract"},{"issue":"1","key":"769_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/db2022-01","volume":"2022","author":"R Pop-Busui","year":"2022","unstructured":"Pop-Busui R, Ang L, Boulton A, Feldman E, Marcus R, Mizokami-Stout K, Singleton JR, Ziegler D. Diagnosis and treatment of painful diabetic peripheral neuropathy. ADA Clin Compendia. 2022;2022(1):1\u201332. https:\/\/doi.org\/10.2337\/db2022-01.","journal-title":"ADA Clin Compendia"},{"issue":"1","key":"769_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s42451-019-00139-8","volume":"3","author":"T Schlereth","year":"2020","unstructured":"Schlereth T. S2k-Leitlinie: Diagnose Und Nicht Interventionelle Therapie Neuropathischer Schmerzen: Zusammenfassung Der Leitlinie Der Deutschen Gesellschaft F\u00fcr Neurologie. DGNeurologie. 2020;3(1):21\u201340. https:\/\/doi.org\/10.1007\/s42451-019-00139-8.","journal-title":"DGNeurologie"},{"issue":"2","key":"769_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000001235","volume":"10","author":"R Freynhagen","year":"2025","unstructured":"Freynhagen R, Baron R, Huygen F, Perrot S. Narrative review of the efficacy and safety of the high-concentration (179\u00a0mg) capsaicin patch in peripheral neuropathic pain with recommendations for clinical practice and future research. PAIN Rep. 2025;10(2): E1235. https:\/\/doi.org\/10.1097\/PR9.0000000000001235.","journal-title":"PAIN Rep"},{"key":"769_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2025.109085","author":"MA \u00dcberall","year":"2025","unstructured":"\u00dcberall MA, Kender Z, Quandel T, Engelen S, Guerra LG, Fajri T, Allen SM, Freitas RL, Eerdekens MH. Progressive improvements in patient-reported outcomes with the high-concentration capsaicin patch: a retrospective cohort study in patients with painful diabetic peripheral neuropathy (CASPAR study). J Diabetes Complications. 2025. https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109085.","journal-title":"J Diabetes Complications"},{"key":"769_CR31","unstructured":"Drummond M, Sculpher MJ, Askews & Holts Library Services, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. (4th ed.). Oxford: Oxford University Press; 2015."},{"key":"769_CR32","unstructured":"Fox-Rushby, J., & Cairns, J. Economic Evaluation. Maidenhead: Open University Press; 2005. https:\/\/researchonline.lshtm.ac.uk\/id\/eprint\/18491"},{"key":"769_CR33","unstructured":"Zhang, K., & Garau, M. International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making; 2020. Retrieved 07 2025, from https:\/\/www.ohe.org\/publications\/international-cost-effectiveness-thresholds-and-modifiers-hta-decision-making"},{"issue":"3","key":"769_CR34","doi-asserted-by":"publisher","first-page":"E150973","DOI":"10.1371\/journal.pone.0150973","volume":"11","author":"C Mankowski","year":"2016","unstructured":"Mankowski C, Patel S, Trueman D, Bentley A, Poole C. Cost-effectiveness of capsaicin 8% patch compared with pregabalin for the treatment of patients with peripheral neuropathic pain in Scotland. PLoS ONE. 2016;11(3):E150973. https:\/\/doi.org\/10.1371\/journal.pone.0150973.","journal-title":"PLoS ONE"},{"issue":"5","key":"769_CR35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1185\/03007995.2011.562885","volume":"27","author":"EP Armstrong","year":"2011","unstructured":"Armstrong EP, Malone DC, McCarberg B, Panarites CJ, Pham SV. Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia. Curr Med Res Opin. 2011;27(5):939\u201350. https:\/\/doi.org\/10.1185\/03007995.2011.562885.","journal-title":"Curr Med Res Opin"},{"key":"769_CR36","doi-asserted-by":"publisher","DOI":"10.61679\/140510121025","author":"D Samper Bernal","year":"2019","unstructured":"Samper Bernal D, Pe\u00f1a Vergara I, Vaamonde Torres N, P\u00e9rez-Mitru A. An\u00e1lisis de Minimizaci\u00f3n de Costes Del Tratamiento Del Dolor Neurop\u00e1tico Perif\u00e9rico En Espa\u00f1a Con Parches Cut\u00e1neos 179 Mg de Capsaicina (8%) Frente a Gabapentinoides. Revista espa\u00f1ola de econom\u00eda de la salud. 2019. https:\/\/doi.org\/10.61679\/140510121025.","journal-title":"Revista espa\u00f1ola de econom\u00eda de la salud"},{"issue":"7","key":"769_CR37","doi-asserted-by":"publisher","first-page":"A383","DOI":"10.1016\/j.jval.2013.08.347","volume":"16","author":"D Trueman","year":"2013","unstructured":"Trueman D, Poole CD, Chambers C, Odeyemi I, Currie C. Evaluation of the cost-effectiveness of the capsaicin patch Qutenzatm for the treatment of peripheral neuropathic pain in the United Kingdom. Value Health. 2013;16(7):A383. https:\/\/doi.org\/10.1016\/j.jval.2013.08.347.","journal-title":"Value Health"},{"issue":"3","key":"769_CR38","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1179\/acb.2008.027","volume":"63","author":"L Annemans","year":"2008","unstructured":"Annemans L, Caekelbergh K, Morlion B, Hans G, De Cock P, Marbaix S. A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain. Acta Clin Belg. 2008;63(3):170\u20138. https:\/\/doi.org\/10.1179\/acb.2008.027.","journal-title":"Acta Clin Belg"},{"key":"769_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-244X-13-1","volume":"13","author":"K Athanasakis","year":"2013","unstructured":"Athanasakis K. Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost-effectiveness analysis for the Greek healthcare setting. BMC Psychiatry. 2013;13:1\u20137.","journal-title":"BMC Psychiatry"},{"issue":"5","key":"769_CR40","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3111\/13696998.2013.773333","volume":"16","author":"P Chevalier","year":"2013","unstructured":"Chevalier P, Lamotte M, Van Campenhout H, Eyckerman R, Annemans L. Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium. J Med Econ. 2013;16(5):596\u2013605. https:\/\/doi.org\/10.3111\/13696998.2013.773333.","journal-title":"J Med Econ"},{"key":"769_CR41","unstructured":"SMC (Scottish Medicines Consortium). Making a submission https:\/\/scottishmedicines.org.uk\/making-a-submission\/. Accessed 17 May 2025."},{"issue":"9","key":"769_CR42","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.pain.2013.04.044","volume":"154","author":"P Mou","year":"2013","unstructured":"Mou P, Turnbull T, Stoker K. Efficacy of Qutenza\u00ae (capsaicin) 8% patch for neuropathic pain: a meta-analysis of the Qutenza Clinical Trials Database. Pain. 2013;154(9):1632\u20139. https:\/\/doi.org\/10.1016\/j.pain.2013.04.044.","journal-title":"Pain"},{"key":"769_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.998904","author":"P Anand","year":"2022","unstructured":"Anand P, Privitera R, Donatien P, Fadavi H, Tesfaye S, Bravis V, Misra VP. Reversing painful and non-painful diabetic neuropathy with the capsaicin 8% patch: clinical evidence for pain relief and restoration of function via nerve fiber regeneration. Front Neurol. 2022. https:\/\/doi.org\/10.3389\/fneur.2022.998904.","journal-title":"Front Neurol"},{"key":"769_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.722875","volume":"12","author":"P Anand","year":"2021","unstructured":"Anand P, Privitera R, Donatien P, Misra VP, Woods DR. Capsaicin 8% patch treatment in non-freezing cold injury: evidence for pain relief and nerve regeneration. Front Neurol. 2021;12: 722875. https:\/\/doi.org\/10.3389\/fneur.2021.722875.","journal-title":"Front Neurol"},{"key":"769_CR45","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002735","author":"M Sendel","year":"2022","unstructured":"Sendel M, Dunst A, Forstenpointner J, H\u00fcllemann P, Baron R. Capsaicin treatment in neuropathic pain: axon reflex vasodilatation after four weeks correlates with pain reduction. Pain. 2022. https:\/\/doi.org\/10.1097\/j.pain.0000000000002735.","journal-title":"Pain"},{"issue":"8","key":"769_CR46","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/j.1526-4637.2008.00423.x","volume":"9","author":"BR Stacey","year":"2008","unstructured":"Stacey BR, Dworkin RH, Murphy K, Sharma U, Emir B, Griesing T. Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. Pain Med. 2008;9(8):1202\u20138. https:\/\/doi.org\/10.1111\/j.1526-4637.2008.00423.x.","journal-title":"Pain Med"},{"key":"769_CR47","unstructured":"Institute for Clinical and Economic Review (ICER). Suzetrigine for Acute Pain: Effectiveness and Value. Institute for Clinical and Economic Review (ICER); 2024. Retrieved July 2025, from https:\/\/icer.org\/assessment\/acute-pain-2025\/"},{"issue":"9","key":"769_CR48","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1111\/pme.12773","volume":"16","author":"G Campbell","year":"2015","unstructured":"Campbell G, Nielsen S, Larance B, Bruno R, Mattick R, Hall W, Lintzeris N, Cohen M, Smith K, Degenhardt L. Pharmaceutical opioid use and dependence among people living with chronic pain: associations observed within the pain and opioids in treatment (POINT) cohort. Pain Med. 2015;16(9):1745\u201358. https:\/\/doi.org\/10.1111\/pme.12773.","journal-title":"Pain Med"},{"key":"769_CR49","unstructured":"Office for National Statistics. National life tables: Scotland; 2024. Retrieved February 2025, from https:\/\/cy.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesscotlandreferencetables"},{"key":"769_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0836-z","author":"C Mankowski","year":"2017","unstructured":"Mankowski C, Poole CD, Ernault E, Thomas R, Berni E, Currie CJ, Treadwell C, Calvo JI, Plastira C, Zafeiropoulou E, et al. Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study. BMC Neurol. 2017. https:\/\/doi.org\/10.1186\/s12883-017-0836-z.","journal-title":"BMC Neurol"},{"issue":"11","key":"769_CR51","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108. https:\/\/doi.org\/10.1097\/00005650-199711000-00002.","journal-title":"Med Care"},{"issue":"2","key":"769_CR52","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40273-022-01218-7","volume":"41","author":"M Hern\u00e1ndez Alava","year":"2023","unstructured":"Hern\u00e1ndez Alava M, Pudney S, Wailoo A. Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from a UK population study. Pharmacoeconomics. 2023;41(2):199\u2013207. https:\/\/doi.org\/10.1007\/s40273-022-01218-7.","journal-title":"Pharmacoeconomics"},{"key":"769_CR53","volume-title":"Estimating EQ-5D by age and sex for the UK","author":"M Hern\u00e1ndez Alava","year":"2022","unstructured":"Hern\u00e1ndez Alava M, Pudney S, Wailoo A. Estimating EQ-5D by age and sex for the UK. Sheffield: Decision Support Unit (DSU), ScHARR, University of Sheffield; 2022."},{"key":"769_CR54","unstructured":"National Institute for Health and Clinical Excellence. BNF (British National Formulary). http:\/\/bnf.nice.org.uk. Accessed Feb 2025."},{"key":"769_CR55","volume-title":"Unit costs of health and social care 2023 manual","author":"KC Jones","year":"2024","unstructured":"Jones KC, Weatherly H, Birch S, Castelli A, Chalkley M, Dargan A, Forder JE, Gao M, Hinde S, Markham S, et al. Unit costs of health and social care 2023 manual. Kent: Personal Social Services Research Unit (University of Kent) & Centre for Health Economics (University of York); 2024."},{"issue":"2","key":"769_CR56","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1464-5491.2006.02057.x","volume":"24","author":"CJ Currie","year":"2007","unstructured":"Currie CJ, Poole CD, Woehl A, Morgan CL, Cawley S, Rousculp MD, Covington MT, Peters JR. The financial costs of healthcare treatment for people with type 1 or type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy. Diabet Med. 2007;24(2):187\u201394. https:\/\/doi.org\/10.1111\/j.1464-5491.2006.02057.x.","journal-title":"Diabet Med"},{"key":"769_CR57","unstructured":"NHS England. 2023\/24 National Cost Collection Data https:\/\/www.england.nhs.uk\/costing-in-the-nhs\/national-cost-collection\/. Accessed Feb 2025."},{"issue":"9","key":"769_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta11090","volume":"11","author":"M Connock","year":"2007","unstructured":"Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11(9):1\u2013171. https:\/\/doi.org\/10.3310\/hta11090.","journal-title":"Health Technol Assess"},{"issue":"5","key":"769_CR59","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1526-4637.2011.01103.x","volume":"12","author":"Md DiBonaventura","year":"2011","unstructured":"DiBonaventura Md, Cappelleri JC, Joshi AV. Association between pain severity and health care resource use, health status, productivity and related costs in painful diabetic peripheral neuropathy patients. Pain Med. 2011;12(5):799\u2013807. https:\/\/doi.org\/10.1111\/j.1526-4637.2011.01103.x.","journal-title":"Pain Med"},{"issue":"1","key":"769_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02175-1","volume":"10","author":"Y Yang","year":"2025","unstructured":"Yang Y, Zhao B, Wang Y, Lan H, Liu X, Hu Y, Cao P. Diabetic neuropathy: cutting-edge research and future directions. Signal Transduct Target Ther. 2025;10(1): 132. https:\/\/doi.org\/10.1038\/s41392-025-02175-1.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"769_CR61","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/j.pain.0000000000000350","volume":"157","author":"BK Bellows","year":"2015","unstructured":"Bellows BK, Nelson RE, Oderda GM, LaFleur J. Long-term cost-effectiveness of initiating treatment for diabetic painful neuropathy with pregabalin, duloxetine, gabapentin, or desipramine. Pain. 2015;157(1):203\u201313. https:\/\/doi.org\/10.1097\/j.pain.0000000000000350.","journal-title":"Pain"},{"issue":"12","key":"769_CR62","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.2165\/0019053-200826120-00007","volume":"26","author":"A O\u2019Connor","year":"2008","unstructured":"O\u2019Connor A, Noyes K, Holloway R. A cost-utility comparison of four first-line medications in painful diabetic neuropathy. Pharmacoeconomics. 2008;26(12):1045\u201364. https:\/\/doi.org\/10.2165\/0019053-200826120-00007.","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"769_CR63","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/dmrr.1225","volume":"27","author":"S Tesfaye","year":"2011","unstructured":"Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconja M, Vinik AI, Boulton AJM, on behalf of The Toronto Expert Panel on Diabetic Neuropathy. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27(7):629\u201338. https:\/\/doi.org\/10.1002\/dmrr.1225.","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"769_CR64","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1155\/2007\/713835","volume":"12","author":"J Lachaine","year":"2007","unstructured":"Lachaine J, Gordon A, Choini\u00e8re M, Collet JP, Dion D, Tarride J-E. Painful neuropathic disorders: an analysis of the R\u00e9gie de l\u2019Assurance Maladie Du Qu\u00e9bec database. Pain Res Manag. 2007;12(1):31\u20137. https:\/\/doi.org\/10.1155\/2007\/713835.","journal-title":"Pain Res Manag"},{"issue":"8","key":"769_CR65","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40266-016-0389-7","volume":"33","author":"G Pickering","year":"2016","unstructured":"Pickering G, Marcoux M, Chapiro S, David L, Rat P, Michel M, Bertrand I, Voute M, Wary B. An algorithm for neuropathic pain management in older people. Drugs Aging. 2016;33(8):575\u201383. https:\/\/doi.org\/10.1007\/s40266-016-0389-7.","journal-title":"Drugs Aging"},{"key":"769_CR66","unstructured":"Datapharm. Pregabalin 150 mg capsules; 2024. Retrieved February 2025, from Electronic Medicines Compendium: https:\/\/www.medicines.org.uk\/emc\/product\/7132\/smpc"},{"key":"769_CR67","unstructured":"Datapharm. Gabapentin 400 mg; 2024. Retrieved February 2025, from Electronic Medicines Compendium: https:\/\/www.medicines.org.uk\/emc\/product\/2360\/smpc"},{"key":"769_CR68","unstructured":"Datapharm. Carbamazepine 200 mg; 2024. Retrieved February 2025, from Electronic Medicines Compendium: https:\/\/www.medicines.org.uk\/emc\/product\/11670\/smpc"},{"key":"769_CR69","unstructured":"Datapharm. Cymbalta 30mg; 2024. Retrieved February 2025, from Electronic Medicines Compendium: https:\/\/www.medicines.org.uk\/emc\/product\/3880\/smpc"},{"key":"769_CR70","unstructured":"Electronic Medicines Compendium. Amitrityline SmPC https:\/\/www.medicines.org.uk\/emc\/product\/14336\/smpc. Accessed Feb 2025."},{"key":"769_CR71","unstructured":"Electronic Medicines Compendium. Tapentadol package leaflet https:\/\/www.medicines.org.uk\/emc\/files\/pil.14759.pdf. Accessed Feb 2025."},{"key":"769_CR72","unstructured":"Electronic Medicines Compendium. Fentanyl SmPC https:\/\/www.medicines.org.uk\/emc\/product\/6939\/smpc. Accessed Feb 2025."}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-025-00769-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-025-00769-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-025-00769-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T17:12:59Z","timestamp":1759252379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-025-00769-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["769"],"URL":"https:\/\/doi.org\/10.1007\/s40122-025-00769-9","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,31]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rita Freitas, Prashant Kandaswamy, Marielle Eerdekens, are employees of Gr\u00fcnenthal GmbH or its affiliates. Miranda Ager was a contractor providing paid services to Gr\u00fcnenthal GmbH via a third-party agency, and is currently an Astellas Pharma Ltd. employee. Anja Pr\u00fcfert is an employee of RJW & Partners, which received funding from Gr\u00fcnenthal GmbH for the preparation of the economic model. Marjolijn van Keep is a contractor providing services to RJW & Partners.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}